

Drug Code: sm7v1v4

Drug Family: small organic molecule (<500 Da)

Drug Category: MOA-B antagonist, reversible

All raw and supporting research data shall convey with purchase.

DATA CONVEYANCE



Disease Category: Parkinson's Disease treatment: click **HERE** to learn more about PD

Drug Design Approach: fragment-based, docking, VLS, MD simulations, ADMET predictions




Docking Results: Candidate "sm7v1v4" exhibited superior

docking performance compared to 15 known experimental and FDA-approved MAO-B inhibitors. Docking (AutoDock VINA) carried out against three MAO-B high-resolution x-ray crystallographic models, including 5MRL, 3PO7 and 10J9 (Figure 1).



MD Results: Docked drug stable over ns-time scales at 310°K in physiological saline, pH7.4 (NPT).








ADMET Profile: Compared to current

FDA-approved MOA-B inhibitors, candidate sm7v1v4 exhibited a moderate to satisfactory ADMET profile, suggesting it as a promising candidate for PD treatment (Figure 2).



Candidate Sm7v1v4 binds non-covalently in the catalytic pocket of MAO-B, which degrades L-dopamine in the central and peripheral nervous systems. Thus, MAO-B inhibition

Figure 2: Comparison of ADMET Profiles for sm7v1v4 and Three FDA-Approved MAO-B Antagonists Large View



alleviates Parkinson's symptoms by augmenting the level of L-dopamine in the brain. In-silico docking and MD indicate sm7v1v4 has a superior target binding and stability profile compared to FDA-approved MAO-B antagonists. Candidate drug sm7v1v4 exhibits a favorable **ADMET profile** with good drug-like properties (QED, MCE/18), ease of synthesis (Synth), good membrane transport (BBB, Caco2), low toxicity (SkinSen, Respira, LC50 DM, hERG), low carcinogenicity (Carcino), and acceptable minimum daily dose profile (FDAMDD) (Figure 2).